10-Q: Veru Inc. Reports Q3 2024 Results, Focuses on Enobosarm Development

Veru Inc. announced its Q3 2024 financial results, highlighting a revenue increase and a strategic focus on enobosarm development for obesity and breast cancer.

Summary

• Veru Inc. reported a net revenue of $4.0 million and a net loss of $11.0 million for the three months ended June 30, 2024.
• Net revenue increased by 18% compared to the same period last year, primarily driven by sales of FC2 in the global public health sector.
• The company's gross profit was $1.3 million, with a gross profit margin of 34%.
• Research and development expenses decreased to $4.9 million, reflecting a strategic shift in focus.
• Selling, general, and administrative expenses decreased to $7.5 million.
• The company recorded a gain on the sale of ENTADFI assets of $0.1 million.
• For the nine months ended June 30, 2024, net revenue was $10.2 million and net loss was $29.3 million.
• The company's cash and cash equivalents stood at $29.2 million as of June 30, 2024.
• Veru is prioritizing the development of enobosarm for obesity and breast cancer, and seeking external funding for sabizabulin for viral-induced ARDS.

Sentiment

Score: 4

Explanation: The document presents mixed results with a revenue increase offset by a net loss and decreased gross profit margin. The company's strategic shift towards enobosarm is positive, but the uncertainty around future funding and the material weaknesses in internal controls are concerning. The loss of S-3 eligibility is a significant negative.

Positives

• The company experienced an 18% increase in net revenue in Q3 2024 compared to the same period last year.
• Veru successfully raised $35.2 million through a public offering of common stock.
• The company has initiated a Phase 2b clinical study for enobosarm, a key focus area.
• Operating expenses, including research and development and selling, general and administrative costs, have decreased.

Negatives

• The company reported a net loss of $11.0 million for the three months ended June 30, 2024.
• Gross profit margin decreased to 34% compared to 37% in the prior year period.
• FC2 net revenues in the U.S. prescription channel decreased by 36% compared to the prior year period.
• The company is not in compliance with a provision of the Jefferies Sales Agreement, which would prevent it from making additional sales under the agreement unless such non-compliance is waived.
• The company is ineligible to file new registration statements on Form S-3 until no earlier than March 1, 2025.

Risks

• The company's ability to raise capital may be impaired due to its ineligibility to file new registration statements on Form S-3 until March 1, 2025.
• There is uncertainty regarding the receipt of future payments from Onconetix, Inc. (formerly Blue Water Vaccines Inc.) related to the sale of ENTADFI assets.
• The company is dependent on the success of its clinical trials and regulatory approvals for its drug candidates.
• There is a risk of delays in clinical trials and regulatory approvals.
• The company faces competition from existing and new competitors.
• The company is subject to risks related to compliance and regulatory matters.
• The company is reliant on major customers and faces risks related to delays in, or failure to make, payment of accounts receivable by major customers.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects to continue investing in research and development, particularly for enobosarm, and is seeking external funding for sabizabulin. Topline results from the Phase 2b QUALITY clinical trial are expected by the end of the fourth calendar quarter of 2024, with results from the extension study expected in the second quarter of calendar 2025.

Management Comments

• Management believes its current cash position and cash expected to be generated from sales of FC2 will be adequate to fund planned operations of the Company for the next 12 months.
• Management intends to be opportunistic when pursuing equity or debt financing.

Industry Context

The company's focus on enobosarm for obesity aligns with the growing market for weight loss drugs, particularly GLP-1 receptor agonists. The development of enobosarm to prevent muscle loss in patients using these drugs addresses a significant unmet need. The company's oncology program targets a specific subset of breast cancer patients, which could provide a new treatment option.

Comparison to Industry Standards

• Veru's revenue growth in the global public health sector for FC2 is consistent with the demand for preventative health products in developing countries.
• The decrease in U.S. prescription channel revenue reflects the challenges faced by telehealth companies, including consolidation and bankruptcies, such as The Pill Club.
• The company's R&D spending is focused on late-stage clinical trials, which is typical for a company at this stage of development.
• The company's cash position is relatively strong compared to other small-cap biopharmaceutical companies, but it is still dependent on future financing to continue operations.
• The company's reliance on a single supplier for a key raw material is a risk that is common in the pharmaceutical industry, but the company is taking steps to mitigate this risk.

Legal Proceedings

• The company is involved in several shareholder lawsuits related to statements about sabizabulin as a treatment for COVID-19.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the risks associated with its drug development programs.
• Employees are impacted by the company's strategic decisions and any potential changes in staffing.
• Customers are impacted by the availability and pricing of the company's products, particularly FC2.
• Creditors are impacted by the company's ability to meet its financial obligations.

Next Steps

• The company will continue to enroll patients in the Phase 2b QUALITY clinical study for enobosarm.
• The company expects topline results from the Phase 2b QUALITY clinical trial by the end of the fourth calendar quarter of 2024.
• The company will continue to seek external funding for the development of sabizabulin for viral-induced ARDS.
• The company will continue to evaluate the collectability of the BWV Promissory Notes for future installments of the purchase price.

Key Dates

Keywords

enobosarm, FC2 Female Condom, sabizabulin, obesity, breast cancer, ARDS, clinical trials, pharmaceutical, biopharmaceutical, telehealth, revenue, financial results